Regarding bone tumors and skeletal metastases, it was recently demonstrated that combined treatments with denosumab associates with an increased abundance of T cells in the tumor microenvironment (TME) and increased amount of anti-tumor cytokines (such as interferon-gamma). This evidence concerns the gene IFNG and neoplasm.